Abstract
Translated and Reprinted with permission from «Chemotherapy Journal» (Chemother J. 2005; 14:22-27)
-
1.
Страчунский Л.С., Козлов С.Н.. Макролиды в современной клинической практике. Смоленск: Русич; 1998.
-
2.
Omura S., editor. Macrolide Antibiotics. 2nd edition. Academic Press; 2002.
-
3.
Schonfeld W., Kirst H.A., editors. Macrolide Antibiotics. Birkhauser Verlag; 2002.
-
4.
Liu L., Roets E., Busson R., e.a. Two novel spiramycins obtained from commercial samples: isolation and elucidation of structure. J Antibiot 1996; 49:398-401.
-
5.
Di Giambattista M., Nyssen E., Engelborghs Y., e.a. Kinetics of binding of macrolides, lincosamides and synergimycins to ribosomes. J Biol Med 1987; 262:8591-7.
-
6.
Bryskier A., Butzler J.-P. Macrolides. In: Antibiotic and Chemotherapy. Finch R.G., e.a.: editors. Churchill Livingstone, 2003. P. 310-25.
-
7.
Козлов Р.С., Кречикова О.И., Сивая О.В. и соавт. Антимикробная резистентность Streptococcus pneumoniae в России: результаты проспективного многоцентрового исследования (фаза А проекта ПеГАС-I). Клиническая Микробиология и Антимикробная Химиотерапия 2002; 4:267-77.
-
8.
Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клиническая Микробиология и Антимикробная Химиотерапия 2005; 7:154-66.
-
9.
Alcaide F., Carratal J., Liyares J., e.a. In vitro activity of eig ht macrolide antibiotics and RP-59500 against viri dans streptococci isolated from blood of neutropenic can cer patients. In: The 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1995: abstr. E51.
-
10.
Labro M.T. Pharmacology of spiramycin. Drug Invest 1993, 6(Suppl. 1):15-28.
-
11.
Rubinstein E. Spiramycin renaissance. J Antimicrob Chemother 1998; 42:572-6.
-
12.
Roche Y., Yoshimori R.N. In vitro activity of spiramycin and metronidazole alone or in combination against clinical isolates from odontogenic abscesses. J Antimicrob Chemother 1997, 40:353-7.
-
13.
Chang H.R., Pechere J.C. In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62993] and A-56268) on Toxoplasma gondii. Antimicrob Agents Chemother 1988; 35:524-9.
-
14.
Voss L.M., Farmer K. Cryptosporidium: newly recognized cause of diarrhea. Curr Ther 1987; 9:23-6.
-
15.
Smith C.R. The spiramycin paradox. J Antimicrob Chemother 1988; 22(Suppl. B):141-4.
-
16.
Bergogne-Berezin E. Predicting antibiotic efficacy in respiratory tract infections. In: The 7th International Congress for Infectious Diseases. Hong Kong, 1996: abstr. 6003.
-
17.
Desnottes J.F. New aspects of spiramycin’s effect on bacteria - host cell interactions. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong, 1996: 4-6.
-
18.
Watanabe T., Kanno M., Tejima E., e.a. Effects of macrolides on ultrastructure of Staphylococcus aureus during the post-antibiotic phase. In: Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy. Berlin, 1991: p. 726-7.
-
19.
Morikawa K., Oseko F., Morikawa S., e.a. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1994; 38:2643-7.
-
20.
Kamimiya S., Weisblum B. Induction of ermCV by 16-memberedring macrolide antibiotics. Antimicrob Agents Chemother 1997; 41:530-4.
-
21.
Brisson-Noel A., Trieu-Cuot P., Courvalin P. Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother 1988; 22(Suppl. B):13-23.
-
22.
Chabbert Y.A. Early studies on in vitro and experimental activity of spiramycin: a review. J Antimicrob Chemother 1988; 22(Suppl. B):1-11.
-
23.
Nakajima Y. Mechanisms of bacterial resistance to macrolide antibiotics. J Infect Chemother 1999; 5:61-74.
-
24.
Kavi J., Webberly J.M., Andrews J.M., e.a. A comparison of the pharmacokinetics and tissue penetration of spiramycin and erythromycin. J Antimicrob Chemother 1988; 22(Suppl. B):105-10.
-
25.
Frydman A.M., Le Roux Y., Desnottes J.F., e.a. Pharmacokinetics of spiramycin in man. J Antimicrob Chemother 1988; 22(Suppl. B):93-103.
-
26.
Bryskier A., Bergogne-Berezin E. Macrolides. In: Antibac te rial and antifungal Agents. Bryskier A., editor. ASM-Press (Washington DC), 2005. In press.
-
27.
Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Prac tice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995: 51-60.
-
28.
Bergogne-Berezin E. Spiramycin concentrations in the human respiratory tract: a review. J Antimicrob Chemother 1988; 22(Suppl. B):117-22.
-
29.
Pocidalo J.-J., Albert F., Desnottes J.F., e.a. Intraphagocytic penetration of macrolides: in-vivo comparison of erythromycin and spiramycin. J Antimicrob Chemother 1985; 16:167-73.
-
30.
Walstad R.A. Predicting spiramycin efficacy in pneumonia and tonsillitis. In: Predicting Antibiotic Response in Respiratory Tract Infections. Highlights from the 7th International Congress for Infectious Diseases. Hong Kong, 1996: 9-10.
-
31.
Pocidalo J.J., Albert F., Desnottes J.F., e.a. Intraphagocytic penetration of macrolides: in vivo comparison of erythromycin and spiramycin. J Antimicrob Chemother 1985; 16(Suppl. A):167-73.
-
32.
Webster C., Ghazanfar K., Slack R. Sub-inhibitory and post-antibiotic effects of spiramycin and erythromycin on Staphylococcus aureus. J Antimicrob Chemother 1988; 22:33-9.
-
33.
Kamme C., Kahlmeter G., Melander A. Evaluation of spiramycin as a therapeutic agent for elimination of nasopharyngeal pathogens. Scand J Infect Dis 1978; 10:135-42.
-
34.
Freeman E. Periodontal disease. Part III. Chemotherapeutics. Can Fam Physician 1988; 34:1395-7.
-
35.
Allen H.H., Khalil M.W., Vachon D., e.a. Spiramycin concentrations in female pelvic tissues, determined by HPLC: a preliminary report. J Antimicrob Chemother 1988; 22(Suppl. B):111-6.
-
36.
Farhat C.K., Calvalho L.H.F.R., Chung S.S., e.a. Toxoplasmosis II. J Pediatr 1981; 51:344-7.
-
37.
Gratzl R., Sodeck G., Platzer P., e.a. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis 2002; 21:12-6.
-
38.
Descotes J. Chemical structures and safety of spiramycin. Drug Invest 1993; 6(Suppl. 1):43-48.
-
39.
Dylewski J., Clecner B., Dubois J., e.a. Comparison of spiramycin and doxycycline for treatment of Chlamydia trachomatis genital infections. Antimicrob Agents Chemother 1993; 37:1373-4.
-
40.
Igea J.M., Quirce S., De la Hoz B., e.a. Adverse cutaneous reactions due to macrolides. Ann Allergy 1991; 66:216-8.
-
41.
Data on file. Sanofi-Aventis. Результаты применения спирамицина при внебольничных пневмониях. Многоцентровое исследование в России.
-
42.
Soekrawinata T., Ibrahim T., Driyatno E. Spiramycin and erythromycin in the treatment of acute tonsillopharyngitis: a comparative study. Curr Med Res Opin 1984; 9:296-300.
-
43.
Manolopoulos L., Adamopoulos C., Tzagourolakis A., et al. Spiramycin versus penicillin V in the empiric treatment of bacterial tonsillitis. Br J Clin Pract 1989; 43:94-6.
-
44.
Gendrel D., Bourrillon A., Bingen E., e.a. Five-day spiramycin vs. seven-day penicillin V in the treatment of streptococcal tonsillitis in children. Clin Drug Invest 1997; 13:338-44.
-
45.
Boezeman A.J., Kayser A.M., Siemelink R.J.G. Comparison of spiramycin and doxycycline in the empirical treatment of acute sinusitis: preliminary results. J Antimicrob Chemother 1988; 22(Suppl. B):165-70.
-
46.
Biermann C., Loken A., Riise R. Comparison of spiramycin and doxycycline in the treatment of lower respiratory tract infections in general practice. J Anmicrob Chemother 1988; 22:152-8.
-
47.
De Cock L., Poels R. Comparison of spiramycin with erythromycin for lower respiratory tract infections. J Antimicrob Chemother 1988; 22:159-63.
-
48.
Krcmery V., Hrachova J., Nogeova A., e.a. Spiramycin versus cefuroxim axetil in initial therapy of pneumonia in children: randomized study. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, abstr. 12.01.
-
49.
Страчунский Л.С., Судиловская Н.Н., Ширяева Н.В. и соавт. Спирамицин (ровамицин) - макролидный анти биотик для пероральной терапии внебольничных пневмоний. Клин. мед 1995, 2:45-8.
-
50.
Mayaud C., Dournon E., Montagne V., e.a. Efficacy of IV spiramycin in the treatment of severe legionnaire’s disease. J Antimicrob Chemother 1988; 22(Suppl. В):179-82.
-
51.
Sznaider N., Plovano S., Bernat M.I., e.a. Effect of spiramycin therapy on human periodontal disease. J Periodontal Res 1987; 22:255-8.
-
52.
Mills W.H., Thompson G.W., Beagrie G.S. Clinical evaluation of spiramycin and erythromycin in control of periodontal disease. J Clin Periodontol 1979; 6:308-16.
-
53.
Poulet P.P., Duffaut D., Barthet P., Brumpt I. Concentrations and in vivo antibacterial activity of spiramycin and metronidazole in patients with periodontitis treated with high-dose metronidazole and the spiramycin/ metronidazole combination. J Antimicrob Chemother 2005; 55:347-51.
-
54.
Segev S., Samra Z., Eliav E., e.a. The efficacy and safety of spiramycin in the treatment of non-gonococcal urethritis in men. J Antimicrob Chemother 1988; 22(Suppl. В):183-8.
-
55.
Машкиллейсон А.Л., Аковбян В.А., Борисенко К.К. и соавт. Ровамицин в лечении урогенитального хламидиоза. Сборник трудов III Российского национального конгресса «Человек и Лекарство», 16-20 апреля 1996 г., Москва. Стр. 164.
-
56.
Grujic J., Djurkovic-Djakovic O., Nikolic A., e.a. Effectiveness of spiramycin in murine models of acute and chronic toxoplasmosis. Int J Antimicrob Agents 2005; 25:226-30.
-
57.
Desmonts G., Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med 1974; 290:1110-6.
-
58.
Wong S.-Y., Remington J.S. Toxoplasmosis in pregnancy. Clin Infect Dis 1994; 18:853-62.
-
59.
Batellier H., Jouk P.S. Value of rovamycin syrup in paediatrics. Lyon Mediterr Med Sud-Est 1982; 17:5411-6.
-
60.
Moskovitz B.L., Stanton T.L., Kusmierek J.J.E. Spiramycin therapy for cryptosporidial diarrhoea in immunocompromised patients. J Antimicrob Chemother 1988; 22(Suppl. B):189-91.
-
61.
Saez-Liorens X., Odio C.M., Umana M.A., e.a. Spiramycin vs. placebo for treatment of acute diarrhea caused by Cryptosporidium. Pediatr Infect Dis 1989; 8:136-40.
-
62.
Raymond J., Kalach N., Bergeret M., e.a. Influence of antimicrobial resistance on eradication of Helicobacter pylori in infected children. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: abstr. LM60.
-
63.
Aujard Y., Kasse M.C. Prophylaxis of bacterial meningitidis in children. Concours Med 1986; 108:559-63.